BRAF and melanoma: The DREAMseq trial recently showed that patients with BRAF V600–mutated advanced melanoma who received nivolumab plus ipilimumab followed by dabrafenib plus trametinib experienced greater OS (72%) compared with patients receiving the converse sequence (52%) (70).